CRL director granted 1,438 restricted stock units

Thompson Craig B. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Thompson Craig B. reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories International director Craig B. Thompson received a grant of 1,438 shares of Common Stock at $177.62 per share. This award is in the form of restricted stock units, increasing his directly held shares to 3,851.

The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.

Insights

Equity Compensation Analyst

Routine director equity grant with time-based vesting.

Director Craig B. Thompson received 1,438 restricted stock units of Charles River Laboratories International at $177.62 per share, a standard equity-based compensation award for board members. His direct holdings rise to 3,851 shares after the grant.

The units vest on the earlier of May 8, 2027 or the business day before the next annual shareholder meeting, aligning director incentives with shareholder interests over a multiyear period. This appears to be a routine governance and compensation event rather than a market-driven trade.

Insider Trade Summary

Grant/Award: 1,438 shares

Grant/Award 1 txn

Insider Thompson Craig B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K

Holdings After Transaction: Common Stock — 3,851 shares (Direct)

Footnotes (1)

1. F1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

Key Figures

RSU grant size: 1,438 shares Grant price per share: $177.62 per share Shares after transaction: 3,851 shares +1 more

4 metrics

RSU grant size 1,438 shares Restricted stock unit award to director on May 8, 2026

Grant price per share $177.62 per share Reported transaction price for RSU grant

Shares after transaction 3,851 shares Craig B. Thompson direct holdings following grant

Vesting latest date May 8, 2027 Latest vesting date for unvested restricted stock units

Key Terms

restricted stock units, annual meeting of shareholders, grant, award, or other acquisition

3 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting of shareholders regulatory

"…or the business day prior to the Company's next annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Craig B. Thompson acquire in the latest CRL Form 4 filing?

Craig B. Thompson received a grant of 1,438 shares of Charles River Laboratories common stock as restricted stock units at $177.62 per share. This award is a form of equity compensation and increases his direct holdings to 3,851 shares after the transaction.

Is the Craig B. Thompson CRL Form 4 transaction a buy or a grant?

The transaction is a grant of restricted stock units, not an open-market purchase. It is coded as “A” for grant or award, reflecting equity compensation given to a director rather than a discretionary buy in the public market.

How many Charles River Laboratories shares does Craig B. Thompson hold after this grant?

After receiving 1,438 restricted stock units, Craig B. Thompson directly holds 3,851 shares of Charles River Laboratories common stock. This figure represents his post-transaction ownership as reported in the Form 4 filing, combining his existing stake with the newly awarded units.

At what price were Craig B. Thompson’s CRL restricted stock units valued?

The 1,438 restricted stock units granted to Craig B. Thompson were valued at $177.62 per share. This price is the reported transaction price per share for the award, providing a reference value for the equity compensation on the grant date.

When do Craig B. Thompson’s CRL restricted stock units vest?

The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day before Charles River Laboratories’ next annual meeting of shareholders. This time-based vesting links the award to ongoing board service and the company’s annual governance cycle.

Does the CRL Form 4 show any stock sales by Craig B. Thompson?

The Form 4 does not report any stock sales by Craig B. Thompson. It shows a single acquisition transaction coded as a grant or award of restricted stock units, indicating an increase, not a reduction, in his reported direct holdings of company shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Craig B.

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,438(1)	A	$177.62	3,851	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Craig B. Thompson, M.D.	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)